➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Moodys
AstraZeneca
McKesson
Colorcon

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208277

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 208277 describes FYCOMPA, which is a drug marketed by Eisai Inc and is included in two NDAs. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the FYCOMPA profile page.

The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the perampanel profile page.
Summary for 208277
Tradename:FYCOMPA
Applicant:Eisai Inc
Ingredient:perampanel
Patents:2
Generic Entry Opportunity Date for 208277
Generic Entry Date for 208277*:
Constraining patent/regulatory exclusivity:
Dosage:
SUSPENSION;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 208277
Mechanism of ActionAMPA Receptor Antagonists
Suppliers and Packaging for NDA: 208277
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FYCOMPA perampanel SUSPENSION;ORAL 208277 NDA Eisai Inc. 62856-290 62856-290-38 340 mL in 1 BOTTLE (62856-290-38)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION;ORALStrength0.5MG/ML
Approval Date:Apr 29, 2016TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Jun 8, 2021Product Flag?YSubstance Flag?YDelist Request?
Patent:  Start TrialPatent Expiration:Jul 1, 2026Product Flag?Substance Flag?YDelist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Baxter
Johnson and Johnson
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.